FindTrial
Sign In

A retrospective Study on the Efficacy and Safety of Xingnaojing Injection in the Treatment of large hemispheric infarction

A retrospective Study on the Efficacy and Safety of Xingnaojing Injection in the Treatment of large hemispheric infarction

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092367
Enrollment
Unknown
Registered
2024-11-14
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

large hemispheric infarction

Interventions

Conventional treatment group:NA
Xingnaojing group:NA

Sponsors

Hubei Provincial Hospital of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1: Meets the diagnostic criteria of TCM and Western medicine for actue cerebral infarction 2: Age >= 18 years old 3: Admission within 14 days of onset 4: CT or MRI shows infarction area = 2/3 of the middle cerebral artery supply area, with or without infarction of the anterior/posterior cerebral artery supply area

Exclusion criteria

Exclusion criteria: Patients with extensive cerebral infarction caused by factors such as tumors, trauma, or subarachnoid hemorrhage complicated by vascular spasm

Design outcomes

Primary

MeasureTime frame
Mortality rate during hospitalization;Discharge mRS score;—

Secondary

MeasureTime frame
Hospitalization days;Evaluation of therapeutic effect of stroke syndrome integral;—

Countries

China

Contacts

Public ContactJing Li

Hubei Provincial Hospital of TCM

synapses1991@126.com+86 157 2706 7053

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026